These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

508 related articles for article (PubMed ID: 27474328)

  • 1. Liver imaging reporting and data system v2014 categorization of hepatocellular carcinoma on gadoxetic acid-enhanced MRI: Comparison with multiphasic multidetector computed tomography.
    Joo I; Lee JM; Lee DH; Ahn SJ; Lee ES; Han JK
    J Magn Reson Imaging; 2017 Mar; 45(3):731-740. PubMed ID: 27474328
    [TBL] [Abstract][Full Text] [Related]  

  • 2. LI-RADS v2014 categorization of hepatocellular carcinoma: Intraindividual comparison between gadopentetate dimeglumine-enhanced MRI and gadoxetic acid-enhanced MRI.
    Song JS; Choi EJ; Hwang SB; Hwang HP; Choi H
    Eur Radiol; 2019 Jan; 29(1):401-410. PubMed ID: 29922928
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diagnostic accuracy of liver imaging reporting and data system (LI-RADS) v2014 for intrahepatic mass-forming cholangiocarcinomas in patients with chronic liver disease on gadoxetic acid-enhanced MRI.
    Joo I; Lee JM; Lee SM; Lee JS; Park JY; Han JK
    J Magn Reson Imaging; 2016 Nov; 44(5):1330-1338. PubMed ID: 27087012
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of gadoxetic acid versus gadopentetate dimeglumine for the detection of hepatocellular carcinoma at 1.5 T using the liver imaging reporting and data system (LI-RADS v.2017).
    Ding Y; Rao SX; Wang WT; Chen CZ; Li RC; Zeng M
    Cancer Imaging; 2018 Dec; 18(1):48. PubMed ID: 30526674
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined hepatocellular cholangiocarcinoma: LI-RADS v2017 categorisation for differential diagnosis and prognostication on gadoxetic acid-enhanced MR imaging.
    Jeon SK; Joo I; Lee DH; Lee SM; Kang HJ; Lee KB; Lee JM
    Eur Radiol; 2019 Jan; 29(1):373-382. PubMed ID: 29955948
    [TBL] [Abstract][Full Text] [Related]  

  • 6. LI-RADS treatment response categorization on gadoxetic acid-enhanced MRI: diagnostic performance compared to mRECIST and added value of ancillary features.
    Kim SW; Joo I; Kim HC; Ahn SJ; Kang HJ; Jeon SK; Lee JM
    Eur Radiol; 2020 May; 30(5):2861-2870. PubMed ID: 32006170
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diagnostic Performance of Gadoxetic Acid-enhanced Liver MR Imaging versus Multidetector CT in the Detection of Dysplastic Nodules and Early Hepatocellular Carcinoma.
    Kim BR; Lee JM; Lee DH; Yoon JH; Hur BY; Suh KS; Yi NJ; Lee KB; Han JK
    Radiology; 2017 Oct; 285(1):134-146. PubMed ID: 28609205
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of gadoxetic acid-enhanced magnetic resonance imaging and contrast-enhanced computed tomography with histopathological examinations for the identification of hepatocellular carcinoma: a multicenter phase III study.
    Tsurusaki M; Sofue K; Isoda H; Okada M; Kitajima K; Murakami T
    J Gastroenterol; 2016 Jan; 51(1):71-9. PubMed ID: 26130441
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intra-individual comparison of gadolinium-enhanced MRI using pseudo-golden-angle radial acquisition with gadoxetic acid-enhanced MRI for diagnosis of HCCs using LI-RADS.
    Kim YC; Min JH; Kim YK; Lee SJ; Ahn S; Kim E; Peeters H
    Eur Radiol; 2019 Apr; 29(4):2058-2068. PubMed ID: 30324388
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ring-Like Enhancement of Hepatocellular Carcinoma in Gadoxetic Acid-Enhanced Multiphasic Hepatic Arterial Phase Imaging With Differential Subsampling With Cartesian Ordering.
    Ichikawa S; Motosugi U; Oishi N; Shimizu T; Wakayama T; Enomoto N; Matsuda M; Onishi H
    Invest Radiol; 2018 Apr; 53(4):191-199. PubMed ID: 29084013
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dynamic enhancement pattern of HCC smaller than 3 cm in diameter on gadoxetic acid-enhanced MRI: comparison with multiphasic MDCT.
    Park VY; Choi JY; Chung YE; Kim H; Park MS; Lim JS; Kim KW; Kim MJ
    Liver Int; 2014 Nov; 34(10):1593-602. PubMed ID: 24673802
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gadoxetic acid disodium-enhanced magnetic resonance imaging outperformed multidetector computed tomography in diagnosing small hepatocellular carcinoma: A meta-analysis.
    Liu X; Jiang H; Chen J; Zhou Y; Huang Z; Song B
    Liver Transpl; 2017 Dec; 23(12):1505-1518. PubMed ID: 28886231
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targetoid hepatic observations on gadoxetic acid-enhanced MRI using LI-RADS version 2018: emphasis on hepatocellular carcinomas assigned to the LR-M category.
    Park HJ; Kim YK; Cha DI; Ko SE; Kim S; Lee ES; Ahn S
    Clin Radiol; 2020 Jun; 75(6):478.e13-478.e23. PubMed ID: 32033745
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Application of Liver Imaging Reporting and Data System version 2018 ancillary features to upgrade from LR-4 to LR-5 on gadoxetic acid-enhanced MRI.
    Lee S; Kim SS; Bae H; Shin J; Yoon JK; Kim MJ
    Eur Radiol; 2021 Feb; 31(2):855-863. PubMed ID: 32809162
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatocellular carcinoma: Can LI-RADS v2017 with gadoxetic-acid enhancement magnetic resonance and diffusion-weighted imaging improve diagnostic accuracy?
    Zhang T; Huang ZX; Wei Y; Jiang HY; Chen J; Liu XJ; Cao LK; Duan T; He XP; Xia CC; Song B
    World J Gastroenterol; 2019 Feb; 25(5):622-631. PubMed ID: 30774276
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Added Value of sequentially performed gadoxetic acid-enhanced liver MRI for the diagnosis of small (10-19 mm) or atypical hepatic observations at contrast-enhanced CT: A prospective comparison.
    Yoon JH; Lee JM; Lee YJ; Lee KB; Han JK
    J Magn Reson Imaging; 2019 Feb; 49(2):574-587. PubMed ID: 30102433
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Abbreviated MRI with optional multiphasic CT as an alternative to full-sequence MRI: LI-RADS validation in a HCC-screening cohort.
    Park SH; Kim B; Kim SY; Shim YS; Kim JH; Huh J; Kim HJ; Kim KW; Lee SS
    Eur Radiol; 2020 Apr; 30(4):2302-2311. PubMed ID: 31858203
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Added Value of a Gadoxetic Acid-enhanced Hepatocyte-phase Image to the LI-RADS System for Diagnosing Hepatocellular Carcinoma.
    Chen N; Motosugi U; Morisaka H; Ichikawa S; Sano K; Ichikawa T; Matsuda M; Fujii H; Onishi H
    Magn Reson Med Sci; 2016; 15(1):49-59. PubMed ID: 26104079
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intra-individual comparison of hepatocellular carcinoma imaging features on contrast-enhanced computed tomography, gadopentetate dimeglumine-enhanced MRI, and gadoxetic acid-enhanced MRI.
    Kim YN; Song JS; Moon WS; Hwang HP; Kim YK
    Acta Radiol; 2018 Jun; 59(6):639-648. PubMed ID: 28825310
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatocellular carcinoma in patients with chronic liver disease: a comparison of gadoxetic acid-enhanced MRI and multiphasic MDCT.
    Baek CK; Choi JY; Kim KA; Park MS; Lim JS; Chung YE; Kim MJ; Kim KW
    Clin Radiol; 2012 Feb; 67(2):148-56. PubMed ID: 21920517
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.